1179533-73-3

Basic information

• Product Name: 5-Fluoro-pyridine-2-carboxaMidine
• Synonyms: 5-Fluoro-pyridine-2-carboxaMidine;5-FluoropicoliniMidaMide
• CAS NO: 1179533-73-3
• Molecular Formula: C₆H₆FN₃
• Molecular Weight: 139.1303432
• Mol File: 1179533-73-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Fluoro-pyridine-2-carboxaMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-pyridine-2-carboxaMidine(1179533-73-3)
• EPA Substance Registry System: 5-Fluoro-pyridine-2-carboxaMidine(1179533-73-3)

Safety Data

• Hazardous Substances Data: 1179533-73-3(Hazardous Substances Data)

Upstream product

• 327056-62-2 5-fluoropicolinonitrile 
• 75-24-1 trimethylaluminum 

Downstream Products

• 1269625-88-8 4,6-dichloro-5-(2-fluoro-benzyl)-2-(5-fluoro-pyridin-2-yl)-pyrimidine 
• 1269625-97-9 4-{5-[(2-Fluorophenyl)methyl]-6-(morpholin-4-yl)-2-(pyridin-2-yl)pyrimidin-4-yl}morpholine 
• 1269626-47-2 5-(2-fluoro-benzyl)-2-(5-fluoro-pyridin-2-yl)-pyrimidine-4,6-diol 
• 1269626-13-2 5-(2-Fluoro-benzyl)-2-(5-methoxy-pyridin-2-yl)-pyrimidine-4,6-diamine 
• 1269626-14-3 5-(2-Fluoro-benzyl)-2-(5-propoxy-pyridin-2-yl)-pyrimidine-4,6-diamine 

Relevant articles and documents

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).